Rhabdomyosarcoma Cell Models for Research

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents, accounting for approximately 3% of all pediatric cancers and 50% of pediatric soft tissue sarcomas. According to the World Health Organization (WHO) Classification of Tumours of Soft Tissue and Bone (2020), RMS comprises distinct subtypes: embryonal (ERMS), alveolar (ARMS), pleomorphic, and spindle cell/sclerosing. Global incidence is estimated at 4.5 cases per million children under 15 years, with a slight male predominance. In the United States, the National Cancer Institute (NCI) SEER program estimates about 400 new cases annually in children and adolescents. Five-year overall survival (OS) for localized disease is approximately 70-80%, but drops to 20-30% for metastatic or recurrent disease. Key risk factors include genetic syndromes such as Li-Fraumeni (TP53 mutations), DICER1 syndrome, and Noonan syndrome, as well as parental smoking and high birth weight. The NCI reports that ARMS has a worse prognosis than ERMS, with 5-year OS of 65% vs. 80% for localized disease. Metastatic RMS remains a major clinical challenge, underscoring the need for novel therapeutic targets and predictive models.

RMS is an ideal disease for mechanistic and translational research due to its well-defined molecular subtypes, characterized by specific genetic alterations. The PAX3-FOXO1 or PAX7-FOXO1 fusion genes define ARMS and are absent in ERMS, providing a clear genetic distinction. Public datasets such as TCGA (The Cancer Genome Atlas) and COSMIC (Catalogue of Somatic Mutations in Cancer) offer comprehensive genomic profiles of RMS, enabling data-driven research. Open questions include the role of fusion proteins in epigenetic regulation, the mechanisms of metastasis, and the identification of subtype-specific vulnerabilities. The availability of patient-derived cell lines and xenografts further enhances RMS as a model for drug discovery and functional genomics.

RMS pathogenesis involves dysregulation of several key pathways:

1. PAX-FOXO1 fusion-driven pathway: In ARMS, the t(2;13) or t(1;13) translocations create PAX3-FOXO1 or PAX7-FOXO1 fusion proteins that act as aberrant transcription factors, driving proliferation and blocking differentiation.

2. RAS/MAPK pathway: ERMS frequently harbors mutations in RAS family genes (NRAS, KRAS, HRAS) and downstream effectors (BRAF, NF1), leading to constitutive MAPK signaling.

3. PI3K/AKT/mTOR pathway: Activated in both subtypes via mutations in PIK3CA, PTEN loss, or RTK overexpression (e.g., IGF1R), promoting survival and growth.

4. p53 pathway: TP53 mutations are common in relapsed and pleomorphic RMS, contributing to genomic instability and chemoresistance.

These pathways converge on transcriptional programs that sustain proliferation, inhibit apoptosis, and block myogenic differentiation.

Data compiled from TCGA, COSMIC, and published genomic studies.

Key signaling networks in RMS include:

• • RAS/MAPK pathway:
• • Mutations in RAS genes or NF1 lead to sustained ERK activation.
• • Promotes cell cycle progression via cyclin D1 and MYC.
• • PI3K/AKT/mTOR pathway:
• • Activated by IGF1R, FGFR4, or PIK3CA mutations.
• • Enhances survival, metabolism, and protein synthesis.
• • PAX-FOXO1 fusion network:
• • Interacts with chromatin remodelers (e.g., CHD4, NCOR1) to alter epigenetic landscapes.
• • Upregulates oncogenes such as MYCN and CCND1.
• • p53 pathway:
• • Inactivated in aggressive subtypes, leading to chemoresistance.
• • Wnt/β-catenin pathway:
• • Implicated in ERMS differentiation block; β-catenin mutations occur in a subset.

These networks are interconnected and offer multiple targets for therapeutic intervention.

Organoids derived from patient tumors or cell lines offer advantages such as 3D architecture, cell-cell interactions, and better recapitulation of drug responses. They can be genetically engineered using CRISPR for functional studies.

Animal models for RMS include:

• • Patient-derived xenografts (PDX):
• • Generated by implanting patient tumor fragments into immunodeficient mice.
• • Preserve tumor heterogeneity and genetic profiles.
• • Genetically engineered mouse models (GEMM):
• • Conditional knockout of Ptch1 or Tp53 in muscle lineage.
• • PAX3-FOXO1 transgenic models develop ARMS-like tumors.
• • Induced models:
• • Carcinogen-induced (e.g., N-ethyl-N-nitrosourea) in rodents.
• • Viral oncogene-driven (e.g., Moloney murine sarcoma virus).

These models are valuable for preclinical drug testing and understanding tumor initiation.

CRISPR/Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications, such as knockout of tumor suppressors or knock-in of oncogenic mutations. Examples include:

• • TP53 knockout in RD cells to study chemoresistance.
• • PAX3-FOXO1 knock-in in mesenchymal stem cells to model ARMS initiation.
• • NRAS Q61H knock-in in ERMS cells to validate targeted therapies.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible tools for drug discovery and functional genomics. These models are engineered using CRISPR and validated by sequencing and functional assays, ensuring reliability.

Gene-edited cell lines allow systematic validation of candidate genes. For example, knockout of PAX3-FOXO1 in ARMS cells abolishes oncogenic proliferation, confirming its driver role. Knock-in of mutant TP53 in ERMS cells demonstrates gain-of-function effects in chemoresistance. These models enable high-throughput screens to identify essential genes and pathways.

Isogenic pairs (e.g., wild-type vs. mutant) are powerful for drug screening. For instance, comparing NRAS-mutant and NRAS-wild-type ERMS cells reveals sensitivity to MEK inhibitors. Resistance models can be generated by chronic drug exposure followed by CRISPR knockout of resistance genes, identifying combination therapies.

CRISPR synthetic lethality screens in RMS cells with specific mutations (e.g., PAX3-FOXO1) can identify novel dependencies. For example, knockout of CHD4 in fusion-positive cells shows selective lethality, suggesting a biomarker for targeted therapy. These screens uncover potential biomarkers for patient stratification.